Engineered human cardiac tissues facilitate progress in regenerative medicine, disease
modelling and drug development. In this Perspective, we reflect on the most notable …

Current methods to differentiate cardiomyocytes from human pluripotent stem cells (PSCs)
inadequately recapitulate complete development and result in PSC-derived cardiomyocytes …

The immature physiology of cardiomyocytes derived from human induced pluripotent stem
cells (hiPSCs) limits their utility for drug screening and disease modelling. Here we show …

The number one cause of human fetal death are defects in heart development. Because the
human embryonic heart is inaccessible and the impacts of mutations, drugs, and …

The cardiomyocyte (CM) subtypes in the mammalian heart derive from distinct lineages
known as the first heart field (FHF), the anterior second heart field (aSHF), and the posterior …

Pluripotent stem-cell-derived cardiomyocytes (PSC-CMs) provide an unprecedented
opportunity to study human heart development and disease, but they are functionally and …

The methods for the culture and cardiomyocyte differentiation of human embryonic stem
cells, and later human induced pluripotent stem cells (hiPSC), have moved from a complex …

An ensemble of in vitro cardiac tissue models has been developed over the past several
decades to aid our understanding of complex cardiovascular disorders using a reductionist …

Cardiovascular disease is a leading cause of death worldwide, and thus there remains great
interest in regenerative approaches to treat heart failure. In the past 20 years, the field of …

Pluripotent stem cells (PSCs) can undergo unlimited self-renewal and can differentiate into
all the cell types present in our body, including cardiomyocytes. Therefore, PSCs can be an …